Effect of Liandouqingmai Recipe on life quality and vascular endothelial injury in patients with coronary heart disease  by Zhu, Hongjun et al.
JTCM |www. journaltcm. com December 15, 2012 |volume 32 | Issue 4 |
Online Submissions:http://www.journaltcm.com J Tradit Chin Med 2012 December 15; 32(4): 529-533
info@journaltcm.com ISSN 0255-2922
© 2012 JTCM. All rights reserved.
CLINICAL OBSERVATION
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Abstract
OBJECTIVE: To observe the effects of Liandouqing-
mai Recipe on life quality and vascular endothelial
injury in patients with coronary heart disease.
METHODS: Capitalized 101 patients with coronary
heart disease were randomly divided into a treat-
ment group (n=45) treated with Liandouqingmai
Recipe and a standard treatment group (control
group, n=56). A normal group of 16 healthy per-
sons was additionally set up. Changes in ET-1 and
NO levels were measured and Seatle Angina Ques-
tionnaire (SAQ) was adopted in studying life quality
before and after treatment for two weeks. The data
were analyzed with SPSS 16.0 statistic software.
RESULTS: The average level of ET-1 in the normal
group was lower and NO higher than that of pa-
tients with coronary heart disease. There was no
significant difference in the average level of ET-1
and NO and in the scores of SAQ [physical limita-
tion (PL), pngina stability (AS), apngina frequency
(AF), treatment satisfaction (TS) and disease percep-
tion (DP)] between the two groups before treat-
ment (P>0.05). But after treatment, the scores of
SAQ (PL, AS, AF, TS, DP) and NO level were higher
than those in the control group, and ET-1 average
level in the treatment group was lower than that in
the control group. The negative relations between
PL and ET-1 and between AF and ET-1 were found
in this study.
CONCLUSION: Liandouqingmai Recipe can raise
scores of SAQ and NO level and decline ET level in
patients with coronary heart disease on the basis of
convertional standard treatment, thus improving
vascular endothelial function and life quality. Life
quality is related to vascular endothelial function.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Coronary heart disease (CHD) has become a
life-threatening disease. Atherosclerosis (AS) is patho-
logical basis of CHD and its basic pathogenesis is defi-
ciency in origin and excess in superficiality, phlegm
and blood stasis. The authors hold that AS is caused by
pathogenic heat, phlegm and blood stasis jointly trans-
ferring into turbidity due to insufficiency of kidney, 1
and "heat, turbidity and deficiency of kidney" is the
most important pathogenesis.2 Therefore, "clearing
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heat, removing turbidity and tonifying the kidney" is
the basic principle for treatment of AS.3
On these grounds, Liandouqingmai Recipe the authors
developed has good clinical effects in prevention and
treatment of AS and CHD. A study has confirmed that
this recipe can decrease low density lipoprotein-choles-
terol level and atherosclerosis-inducing index in plasma
of atherosclerosis patients.4 It is verified that the recipe
can further decrease brachial-ankle pulse wave velocity
and increase ankle-brachial index in atherosclerosis pa-
tients on the basis of standard treatment.5 So it has a
good effect of improving arterial rigidity degree and de-
creasing ultra-sensitive C-response protein (CRP), pe-
ripheral white blood cells (PBL), interleukin-6 (IL-6)
and IL-10 with a good anti-inflammatory action.4,6 At
the same time, it can decline endothelin-1(ET-1)level
and raise nitric oxide (NO) level in patients with CHD
on the basis of standard treatment6 so as to improve
vascular endothelial function.
This trial was designed to observe the effects of Lian-
douqingmai Recipe on life quality of CHD patients
and investigate the effects of the recipe on life quali-
ty scores of Seattle angina questionnaire (SAQ), ET-1
and NO in patients with CHD and the correlations
between scores on one hand and ET-1 and on the
other hand. This study approved by the appropriate
ethics committees was performed in accordance with
the ethical standards laid down in the Declaration of
Helsinki.
METHODS
Diagnostic criteria of coronary heart disease
Diagnosis of coronary heart disease refers to the nam-
ing and diagnostic criteria of ischemic heart disease is-
sued by International Heart Associa tion / Internation-
al College of Cardiology and the Named Standardiza-
tion Joint Task Team of WHO.7
General data
One hundred and one CHD patients and 16 healthy
volunteers took part in this study. The 101 inpatients
in the heart department of internal medicine, Wuxi
Hospital affiliated to Nanjing University of Traditional
Chinese Medicine, from June 2007 to December 2009
were randomly divided into a Liandouqingmai Recipe
group (treatment group) and a standard treatment
group (control group) according to random number ta-
ble. Among 45 cases in the treatment group were 20
males and 25 females aged 51-87 years, 71±8 years on
average, with illness course from 2 h to 28 years, 9±11
years on average. Among 56 cases in the control group
were 24 males and 32 females aged 54-86 years, 70±9
years on average, with illness course from 1 h to 40
years, 9±13 years on average. There were no statistical
differences in age, sex and illness course between the 2
groups. 16 healthy volunteers in the normal control
group (normal group) were staff members and workers
at their posts or retirees in this hospital after their age
and sex had been matched. All the persons voluntarily
taking part in this research signed their fact-knowing
agreement prior to their inclusion in the study and
were approved by the hospital and the Moral and Ethi-
cal Committee.
Criteria of inclusion
Patients should meet the diagnostic criteria of coronary
heart disease and any one item of the following condi-
tions: remote myocardial infarction, hemodynamically
stable acute myocardial infarction or angina pectoris,
positive sports plate test with clinical symptom and
sign, at least one blood vessel or at least one part of a
vessel narrowing over 60% found with coronary arteri-
ography. Patients should voluntarily sign a fact-know-
ing agreement.
Criteria of exclusion
Excluded from the trial were patients with insufficien-
cy of the spleen-yang in Traditional Chinese Medicine,
hemodynamically unstable angina pectoris and acute
myocardial infarction, severe arrhythmia, other inflam-
matory diseases, severe heart diseases, severe dysfunc-
tion of liver and kidney, severe primary diseases of lung
and brain, psychosis, or refusing to sign a fact-knowing
agreement.
Treatment methods
The patients in the treatment group and the control
group were treated with a standard treatment, includ-
ing nitrate type drugs [such as isosorbide mononitrate
tablets (Southern Betty Pharmaceutical Co., Ltd, Chi-
na)20 mg, twice each day, isosorbide dinitrate(Nanjing
Baijingyu Pharmaceutical Co., Ltd, China) 5-10 mg,
thrice daily, and nitroglycerin(Guangzhou Baiyun
Mountain Ming Xing Pharmaceutical Co., Ltd, China)
according to patient's condition], aspirin(Bayer Phar-
maceutical Co., Ltd, Germany) 100-300 mg, once
each day, statins type drugs for regulating lipids [such
as atovastatin calcium tablets(Pfizer, New York, The
United States)10-20 mg, once each day, and fluovas-
tatin sodium capsules (Beijing Novartis Pharma Com-
pany Limited, Switzerland) 40 mg, once each night],
angiotensin-converting enzyme inhibitor [Benazepril
tablets (Beijing Novartis Pharma Company Limited,
Switzerland) 10 mg, once each day, peduopril tablets
(Les Laboratoires Servier Industrie, France) 4 mg, once
daily. For the patient with no contraindication, β-re-
ceptor blockers, etc. [Metoprolol tablets(Astrazeneca
Pharmaceutical Co., Ltd, Sweden-Britain) 6.25-100
mg, twice each day, and bisoprolol tablets(Merck Co.,
Ltd, Germany) 2.5-5.0 mg, once each day] were used
for a long time in a whole course. There were no statis-
tical differences between the two groups in drug kind,
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dose and therapeutic course for the standard treatment.
For the patients in the treatment group, Liandouqing-
mai Recipe composed of Lianqiao (Fructus Forsythiae)
15 g, Huanglian (Rhizoma Coptidis) 3 g, Yeliaodou
(Glycine soja Sieb) 15 g, Chishao (Radix Paeoniae) 10 g,
Laifuzi (Semen Raphani) 10 g, and so on was added to
the standard treatment. The recipe was prepared by
Pharmaceutics Department in the hospital and the
herbs were purchased from Tianjiang Pharmaceutical
Factory. 250 mL of the decoction was orally taken
twice a day for two weeks as one therapeutic course.
Collection and preservation of samples
Two of 4 mL venous blood taken from the patient on
empty stomach in themorningwithin 24 h after hospital-
ization was slowly poured into a tube with 30 μL 10%
EDTA. The mixture stood for 1 h at room tempera-
ture and centrifuged at 3000 r/min for 10 min. The
supernatant was taken and poured into a tube, which
was sealed and kept at -70℃ for ET-1 determination.
The other 2 mL venous blood poured into a dry
tube stood for 1 h at room temperature and centri-
fuged for 10 min at 3000 r/min. A part of the super-
natant put in a tube was sealed and kept at -70℃ for
NO determination.
Observation indexes and determination methods
ET-1 radioimmunoassay kit made by Beijing North
Biotechnology Institute was used for automatic deter-
mination of ET-1 with GC911 radioimmunoanalyser
(Hkust Innovation Co., Ltd, China). NO kit pur-
chased from Nanjing Jiancheng Bioengineering Insti-
tute was used for determination of NO with 751G
spectrophotometer (Shanghai Analysis Instrument
plant, China).
Scores of SAQ, including physical limitation (PL), an-
gina stability (AS), angina frequency (AF), treatment
satisfaction (TS) and disease perception (DP), were
graded by the same deputy chief physician through pa-
per SAQ scales.
After treatment for two weeks, collection and preserva-
tion of the above-mentioned samples and scores grad-
ing were repeated. ET-1 and NO were determined to-
gether once every 6 months.
Statistical analysis
The data were analyzed with SPSS 16.0 software packet
(SPSS Company, Chicago, The United States). The
measurement data were expressed as mean±SD. Two-
side student-t test of two independent samples was
used for comparison of therapeutic effects between
groups, and two-side student-t test of paired samples
was used for comparison of therapeutic effects before
and after treatment in groups. Correlation was analyzed
with Pearson correlation. Significant level is P<0.05.
RESULTS
Effects of Liandouqingmai Recipe on scores of SAQ
Before treatment, there were no significant differences
in the scores of PL, AS, AF,TS andDP between the treat-
ment group and the control group (P>0.05,Table 1).
After treatment in the control group, the score of AS
increased from 62±22 to 80±13, DP from 58±18 to
71±17 (both P<0.01), and PL, AF and TS did not sig-
nificantly change. However, in the treatment group,
the score of PL increased from 63±13 to 78±10, AS
from 63±24 to 89±10, AF from 65±22 to 85±12, TS
from 67±14 to 82±12 and DP from 61±18 to 81±17
(all P<0.01). After treatment, all the scores of PL, AS,
AF, TS and DP were significantly higher in the treat-
ment group than those in the control group (PL from
59±12 to 78±10, AS from 63±24 to 89±10, AF from
71±13 to 85±12, TS from 67±10 to 82±12, DP from
71±17 to 81±17 (all P<0.01).
Effects of Liandouqingmai Recipe on ET-1 and NO
levels
Before treatment, the level of ET-1 and NO was (91±
13) ng/L and (92 ± 18) μmol/L respectively in the
CHD groups (the control group and the treatment
group), and (42 ±14) ng/L and (124±27) μmol/L in
the normal group respectively. The ET-1 level before
treatment in the CHD groups was significantly higher
and NO lower than those in the normal group (both
P<0.05, Table 1).
Before treatment, there were no significant differences
in ET-1 and NO levels between the treatment group
and the control group (P>0.05). After treatment, ET-1
level significantly decreased (P<0.05) and NO did not
significantly change in the control group; ET-1 level de-
creased and NO increased significantly in the treat-
ment group (both P<0.05), NO level was significantly
higher in the treatment group than that in the control
group (both P<0.05), and there was no significant dif-
ference in ET-1 level between the two groups (Table 1).
Correlativity between scores of SAQ and endothelial
function
There was negative correlation between ET-1 and PL,
Table 1 Effects of Liandouqingmai recipe on ET-1 and NO
levels
Notes: ET-1: endothelin-1; NO: nitric oxide; aP<0.05 as
compared with the datum before treatment; bP<0.05 as
compared with the datum in the control group.
Group
Normal
group (n=16)
Control
group (n=56)
Treatment
group (n=45)
-
Before
After
Before
After
ET-1
(pg/mL)
42±14
90±13
64±10a
92±12
59±9a
NO
(μmol/L)
124±27
92±18
92±17
92±18
117±22ab
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AF (r=-0.144, -0.179, P<0.05) and positive correlation
between NO and PL (r=0.134, P=0.056, Table 2).
DISCUSSION
Quality of life is defined as an individual's perceptions
of life condition under different culture background
and value system in relation to its goals, expectations,
standards and concerns. 29% of the patients with pri-
mary stable angina experience angina once or more a
week, which is associated with greater physical limita-
tions and worse quality of life than those with minimal
angina (less than once a week over the preceding 4
weeks).8 Therefore, the aim of treatment of CHD is
not only to ease the clinical symptoms but also to im-
prove the patients' quality of life. This is to evaluate
the effect of drugs. Drug treatment is one of the impor-
tant indexes. At present, SAQ is widely used to clinical-
ly evaluate the life quality of CHD patients.
This scale is divided into 5 categories and 11 entries:
limited degree of body activities (question 1), stable
state of angina pectoris (question 2), heart attacks
(question 3-4), treatment satisfaction (question 5-8),
disease understanding (question 9-11). The total score
is 100 points. The higher the score, the better the life
quality and the body function of patients.
Research shows that the scale's reliability, validity and
reaction degree are good,9 it can be used to evaluate life
quality of CHD patients.
Vascular endothelial damage is the key factor to coro-
nary heart disease.10 Severe endothelial dysfunction in
the absence of obstructive coronary artery disease is as-
sociated with increased cardiac events. It supports the
concept that coronary endothelial dysfunction may
play a role in the progression of coronary atherosclero-
sis.11 Endothelial dysfunction is a systemic disorder and
a key variable in the pathogenesis of atherosclerosis and
its complications. Current evidence suggests that endo-
thelial status is not determined solely by the individual
risk factor burden but may be regarded as an integrated
index of all atherogenic and atheroprotective factors
present in an individual.12 ET is the most important
blood-vessel-shrinking material secreted by endothelial
cells. When ET content increases, local blood vessels
strongly contract, making calcium enter cells to cause
excessive calcium in cells.13 Among three ET isomers,
ET-1 has the strongest effect of shrinking blood vessels.
In vitro studies show that ET-1 has 10 times stronger
effect of shrinking blood vessels than angiotensinⅡ.14
NO is unstable and small gas molecules with a variety
of biological activities and extremely short half-life. It
has been confirmed as an endothelial-derived diastolic
factor. NO with a strong vascular diastolic effect can in-
hibit platelet to be gathered and activated and protect
blood vessels through the collaborative prostaglandins.
In addition, NO can restrain neutrophils and mononu-
clear cells from infiltration into and adhesion to blood
vessel walls, inhibit vascular smooth muscle cells to pro-
liferate and resist thrombosis.
NOandET,mutually antagonistic vascular activemateri-
als released by endothelial cells, play an important role in
adjusting and maintaining endothelial function. A study
demonstrates that high level of ET-1 in combination
with specific PKC and eNOS can inhibit endothelial
cells to release NO, thus causing spasm of coronary arter-
ies and ischemia andhypoxia of cardiacmuscles.15
Our previous researches have confirmed that the ET-1
level of CHD patients is significantly higher and NO
concentration is significantly lower than those in the
normal group, and No is negatively related to IL-10 (r=
0.152).4 In this study, ET-1 was negatively related to
PL and AF (r=-0.144, -0.179, P<0.05) and NO posi-
tively related to PL (r=0.134, P=0.056), indicating that
damage to endothelial function is closely related to
CHD patients' life quality, especially PL and AF.
We have found that Liandouqingmai Recipe can de-
cline ET-1 level and raise NO level in patients with cor-
onary heart disease on the basis of standard treatment.4
This study suggests better endothelial function can im-
prove the life quality of CHD patents. After treatment,
ET-1 level significantly decreased (P<0.05) and NO
did not significantly change in the control group, ET-1
level decreased and NO increased significantly in the
treatment group (both P<0.05), and NO level was sig-
nificantly higher in the treatment group than that in
the control group (both P<0.05) with no significant
difference in ET-1 level between the two groups. In the
control group, scores of AS and DP increased while
PL, AF and TS did not significantly change. In the
treatment group, scores of PL, AS, AF, TS and DP all in-
creased significantly, and after treatment, all the scores
of PL, AS, AF, TS and DP were significantly higher in
the treatment group than those in the control group (all
P<0.01). The results show that the standard treatment
can improve CHD patients' endothelial function and
life quality, and the treatment group additionally using
Liandouqingmai Recipe can more effectively improve
endothelial function and life quality, reduce PL, im-
prove AS, decline AF and enhanceTS and DP.
Based on the above-mentioned trial, we may conclude
that Liandouqingmai Recipe can raise scores of SAQ
and NO level and decline ET level in patients with cor-
onary heart disease on the basis of standard treatment,
so as to improve mutually related vascular endothelial
function and life quality.
Table 2 Correlativity between scores of SAQ and endothelial
function
Notes: ET-1: endothelin-1; NO: nitric oxide; PL: physical
limitation; AS: angina stability; AF: angina frequency; TS:
treatment satisfaction; DP: disease perception; aThere was
significant correlation at 0.05 level (bilateral).
ET-1
NO
PL
-0.144a
0.134
AS
-0.068
0.028
AF
-0.179a
0.052
TS
-0.110
-0.036
DP
0.016
0.060
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